OBJECTIVE: Studies reveal that prenatal polycyclic aromatic hydrocarbon (PAH) exposure is associated with adverse pregnancy outcomes, including preterm birth. PAHs are generated through incomplete combustion of fossil fuels and are also found in tobacco smoke. In this study we utilized mass spectrometry and RNA-Seq in the placenta to measure alterations of the placental transcriptome with PAH exposures. STUDY DESIGN: PAHs were extracted from placenta (n¼27) and analyzed via gas chromatography and mass spec (Agilent 7890A and 5975C). Benzo[a]pyrene (BaP), and Benzo[b] fluoranthene (BbF) quantification was performed using universal standards. RNA was extracted from the same samples, and utilized for RNA-Seq. DNA sequencing libraries were generated from the cDNA and cluster generation and sequencing was performed on the Illumina cBot station and Illumina Hiseq 2000. Sequenced reads were mapped to the human reference genome (GRCh38) with HISAT2 and assigned to genomic features with StringTie. Samples were stratified into high and low exposure groups based on mass spec results. Differential expression was determined using a parametric test and the R statistical system, and genes with a false discovery rate (FDR) multiple testing corrected value < 0.05 were considered deferentially expressed. Gene set enrichment and ontology analysis was performed with GSEA. RESULTS: Levels of placental BaP and BbF were highly correlated (Pearsons r¼0.954, p<0.001). Expression levels of 500 genes (p<0.05) were significantly changed (figure); 168 genes were upregulated, and 322 down regulated in the high exposure group compared with low exposure. Analysis of 1630 networks in GSEA revealed alterations in immune and inflammatory responses with PAH exposure (-4.17223 and -3.3718 respectively). Of interest, response to prostaglandins was significantly altered (-1.9667). CONCLUSION: We found significant correlations between PAHs in the placenta, which validates the technique as reports have shown that we are exposed to mixtures of PAHs through ambient air. The finding that the placental transcriptome is altered with PAH exposures requires further investigation in order to uncover mechanisms behind the adverse effects of PAH exposure in utero. PAH exposure has been associated with preterm birth, and follow up of these altered networks, including response to prostaglandins will help to further our understanding of these adverse effects.
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OBJECTIVE: Obesity in pregnancy bears unique maternal and fetal risks, including an increased risk for gestational diabetes and metabolic perturbations in the offspring. Obesity has also been associated with chronic inflammation, including elevated levels of IL-6 and TNF-alpha. Levels of serum lipopolysaccharides (LPS) rise with increased gut permeability, and have been implicated in driving this inflammation, a phenomenon called metabolic endotoxemia (ME). GLP-2, a proglucagon-derived peptide believed to be integral in maintaining the integrity of the intestine in the face of LPS -mediated endotoxemia. However, variations in these likely molecular mediators in pregnancies among normal, obese, and women with excess weight gain have not yet been explored. We hypothesized that obesity and/or excess weight gain in pregnancy would be associated with an increase in maternal and neonatal markers of ME, as well as GLP-2. STUDY DESIGN: Paired maternal and neonatal (cord blood) serum samples (n¼161) were obtained from our pregnancy biobank repository. Serum levels of LPS, endotoxin core antibody (EndoCAbIgM), and GLP-2 were measured by ELISA. IL-6 and TNF-alpha were measured using a Milliplex assay. Results were stratified by maternal body mass index (BMI), diabetes, and gestational weight gain (GWG). RESULTS: Maternal IL-6 is significantly decreased in the obese, diabetic cohort compared with the non-obese, non-diabetics (95.28 vs. 99.48 pg/mL, p¼0.047) while GLP-2 is significantly increased (1.92 vs. 2.89 ng/mL, p¼0.026). Neonatal TNF-alpha is significantly decreased in the obese cohort compared to the non-obese (12.43 vs. 13.93 pg/mL, p¼0.044). Maternal GLP-2 is significantly increased in women with excess GWG compared with those with normal GWG (2.27 vs. 1.48 ng/mL, p¼0.014, Figure) . We further found that neonatal IL-6 and TNF-alpha are negatively correlated with maternal BMI (-0.186, p¼0.036 and -0.179, p¼0.044 respectively), and that maternal and neonatal IL-6 showed a positive correlation (0.348, p<0.001). CONCLUSION: While we observed altered levels of markers of inflammation (IL-6 and TNF-alpha) with maternal obesity and diabetes, no changes in LPS or endoCAb-IgM were observed. We hypothesize that the increased GLP-2 levels in maternal serum in association with excess GWG may protect against ME in pregnancy.
584 Maternal-fetal medicine physician's opinions regarding risk of death and medically indicated termination of pregnancy 
STUDY DESIGN:
We conducted a survey of all SMFM members in 2018. The primary outcomes were the risk of death at which the member would recommend TOP or consider it to be medicallyindicated. The primary exposures were demographic information, experience, and answers to questions regarding the safety of TOP. Chi-squared analyses were utilized in order to determine if significant differences existed between groups. RESULTS: Of the 2,685 SMFM members, 98 responded. 49% would recommend TOP for a patient with greater than 10% chance of death, and 78% would consider TOP to be medically indicated anyone with greater than 1% chance of death. There were significant regional differences, and 49% percent of respondents had misconceptions regarding TOP. Region of origin, residency, and misconceptions regarding TOP were associated with the opinion that TOP should be recommended (OR 2.49, p¼0.046) or considered medically indicated (OR 3.54, p¼0 .004) at higher risk of maternal death than 10% or 1%, respectively. 46.9% of respondents overestimated the highest reported risk of death after second trimester TOP in the United States by one thousand fold or more. CONCLUSION: Significant differences of opinion exist amongst MFM physicians regarding the risk of death at which to recommend or consider a TOP medically indicated. MFMs who are well informed about TOP were more likely to recommend TOP or consider it to be medically-indicated at lower chances of mortality than 10% and 1%, respectively. OBJECTIVE: Past studies on prenatal care (PNC) have focused on maternal outcomes associated with inadequate PNC and maternal and social predictors for inadequate or delayed PNC. We aimed to determine the effect of delayed initiation of PNC on adverse maternal outcomes. STUDY DESIGN: A retrospective cohort study of non-anomalous, singleton pregnancies comparing adverse maternal outcomes between women who initiated prenatal care early vs. delayed (>20-week gestational age) at Oregon Health and Science University from 2009-2015, stratified by obesity at the time of delivery (obese ¼ BMI30, non-obese ¼ BMI <30). Chi-square was used to compare rates of adverse perinatal outcomes between early and delayed care
